Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Diabetes and COVID-19: The potential role of mTOR

B. Pinchera *, R. Scotto, A.R. Buonomo, E. Zappulo, F. Stagnaro, A. Gallicchio, G. Viceconte, A. Sardanelli, S. Mercinelli, R. Villari, M. Foggia, I. Gentile, Federico II COVID Team

Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples “Federico II”, Naples, Italy.

**ARTICLE INFO**

**Keywords:**
- Diabetes
- SARS-CoV-2
- COVID-19
- mTOR

**ABSTRACT**

Diabetes is the most frequent comorbidity among patients with COVID-19. COVID-19 patients with diabetes have a more severe prognosis than patients without diabetes. However, the etiopathogenetic mechanisms underlying this more unfavorable outcome in these patients are not clear. Probably the etiopathogenetic mechanisms underlying diabetes could represent a favorable substrate for a greater development of the inflammatory process already dysregulated in COVID-19 with a more severe evolution of the disease. In the attempt to shed light on the possible etiopathogenetic mechanisms, we wanted to evaluate the possible role of mTOR (mammalian Target Of Rapamycin) pathway in this context.

We searched the PubMed and Scopus databases to identify articles involving diabetes and the mTOR pathway in COVID-19.

The mTOR pathway could be involved in this etiopathogenetic mechanism, in particular, the activation and stimulation of this pathway could favor an inflammatory process that is already dysregulated in itself, while its inhibition could be a way to regulate this dysregulated inflammatory process. However, much remains to be clarified about the mechanisms of the mTOR pathway and its role in COVID-19.

The aim of this review is to understand the etiopathogenesis underlying COVID-19 in diabetic patients and the role of mTOR pathway in order to be able to search for new weapons to deal with this disease.

1. mTOR pathway and COVID-19

mTOR (mammalian Target Of Rapamycin) is a crucial pathway in many physiological processes, such as cell cycle progression, transcription, translation, differentiation, apoptosis, motility and cell metabolism. mTOR plays a central role in the regulation of cell growth and proliferation, at the translational level, and in cell cycle progression, in many physiological processes, such as cell cycle progression, transcription, translation, differentiation, apoptosis, motility and cell metabolism. mTOR plays a central role in the regulation of cell growth and proliferation, at the translational level, and in cell cycle progression, in particular, mTOR also modulates protein synthesis through regulation of RNA polymerases I and III, which are responsible for ribosomal and transfer RNA transcription (Fig. 1). It is known that the mTOR pathway plays a fundamental role in viral translation [1]. It is already known that several viruses such as Adenovirus, Cytomegalovirus, Herpesvirus and the same Middle Eastern Respiratory Syndrome Coronavirus (MERS – CoV) use the mTOR pathway to be able to replicate [2,3]. In particular, the mTOR pathway also appears to be involved in the life cycle of SARS-CoV-2 infection [4]. The antiviral properties of mTORs have been known and ascribed to a variety of mechanisms [5].

Blockade of the mTOR pathway induces an inhibition of protein synthesis and prevents the activation of lymphocytes [6,7]. Furthermore, it inhibits the expression of proinflammatory cytokines, such as IL-2, IL-6 and IL-10 and suppresses the cytokine storm [2]. These data were observed with the use of rapamycin, an inhibitor of the mTOR pathway. In particular, rapamycin is able to interrupt the cell cycle of T cells during their transition from G1 to S phase by inhibiting signal-mediated interleukin [8–11]. The authors Husain and Byrareddy evaluated the different uses of Rapamycin, highlighting that this drug with its action can help control the synthesis of viral particles, cytokine storms and helps fight the disease thanks to its anti-aging effects [4]. Maiese et al. showed that mTOR pathways in combination with AMPK (Adenosine Monophosphate-activated Protein Kinase) may offer valuable targets for controlling cell damage, oxidative stress, mitochon- drial dysfunction and the onset of hyperinflammation, a significant dysregulation associated with COVID-19 [5]. mTOR inhibitors in preventing COVID-19 severity were examined in an article by Zheng et al., where...
the potential role of these drugs in reducing the possible development of the dysregulated inflammatory process was shown and therefore their possible role in preventing severe forms of disease was hypothesized [12]. This hypothesis was based on the ability of mTOR inhibitors to limit the proliferation of memory B cells and T cell responses [10]. Ramaiah et al. showed a potential action of rapamycin in inhibiting SARS-CoV-2 infection and replication in human lung cells [13,14]. Sargiacomo et al. evaluated the use of azithromycin, doxycycline and rapamycin, drugs that inhibit protein synthesis, demonstrating that these drugs reduced inflammation and viral replication. Mechanistically, this is due to the fact that cytokines and viruses are both made up of proteins. Both use cellular ribosomes for protein translation [15].

The inhibitory action on the mTOR pathway can help control the synthesis of viral particles and regulate cytokine storms [16–18]. mTOR inhibitors also suppress early B cell production and reduce antigen-specific memory B cell populations. Therefore, SARS-CoV-2 infected patients treated with mTOR inhibitors can be expected to have reduced early cross-reactive antibody production and thus less antibody-dependent enhancement. Therefore, mTOR inhibitors could act as a double-edged sword in COVID-19 patients [19,20]. From the various studies reported it emerges that the inhibitory drugs of the mTOR pathway, through the regulation of T cells, the reduction of viral replication and the reduction of the production of pro-inflammatory cytokines, would seem to be able to play a role in the regulation and management of that inflammatory process [21].

2. Outcomes of COVID-19 infection in patients with diabetes

It is well known that patients suffering from COVID-19 (CoroNaVIrus Disease-19 (COVID-19) with diabetes have a poorer prognosis than patients without diabetes. In fact, the disease is more severe and the mortality rate higher in patient with diabetes than in those without [22–25]. In addition hyperglycemia, regardless of the diagnosis of diabetes, has been implicated in a poor prognosis in patients with COVID-19 [26,27]. A prevalence of about 10% of diabetes has been reported in patients with COVID-19, thereby constituting the most frequent co-morbidity [28–30]. Moreover, this prevalence fluctuated between 7% and 21% [10]. The prevalence of diabetes in COVID-19 patients varied widely depending on the geographic areas considered [31,32]. Additionally, patients with diabetes and COVID-19 have an approximately three times greater relative risk of developing serious disease and a higher mortality rate than patients with COVID-19 and without diabetes. [33–38]. Several studies compared COVID-19 patients with diabetes to those without. A retrospective observational study from 88 US hospitals (n = 570), showed a significant increase in death rate in patients with diabetes compared to those without (28.8% versus 6.2%, p < 0.001) [27]. A higher death rate was reported in patients with COVID19 who had uncontrolled hyperglycemia (n = 184) (41.7 versus 14.8%, p < 0.001) [39,40]. Furthermore, the patients with diabetes had greater odds of ICU (Intensive Care Unit) admission (OR 1.59, 95% CI 1.01–2.52), mechanical ventilation (OR 1.97, 95% CI 1.21–3.20), and death (OR 2.02, 95% CI 1.01–4.03) [22]. A retrospective study (n = 7,337) highlighted increased mortality in COVID-19 patients with diabetes (n = 810) compared to those without (n = 6,385) (HR 1.49, 95% CI 1.13–1.96, p = 0.005) [41]. Another study showed an independent association of glycemic control to increased mortality in people with COVID-19 [42]. However, the etiopathogenetic mechanisms underlying this more unfavorable outcome in this category of patients are not very clear.

3. Insulin and COVID-19

In several studies, the potential etiopathogenetic role of insulin in patients with COVID-19 and type 2 diabetes mellitus has been noted. In particular, it has been observed that, following the immune activation, lymphocytes overexpress insulin receptors and therefore dysregulated insulin signaling in immune cells could be involved in the dysregulated immune response in patients with COVID-19 and diabetes, explaining the unfavorable outcome. In fact, insulin would be able to activate and stimulate the PI3K/Akt/mTOR pathway (Phosphatidyl Inositol 3-
Diabetes Research and Clinical Practice 186 (2022) 109813

3

stimulating the pathway PI3K/Akt/mTOR [49]. Another possible pro-
inducible factor 1-alpha (HIF-1 alpha) [47]. In turn involved in the
inflammatory role [50]. Furthermore, various immune cells also ex-
press IGF-1 receptors, which also activate the PI3K/Akt/mTOR
pathway. In this respect, both the IGF-1 receptor and the insulin/IGF-1
hybrid receptors can be activated by insulin; however, at different af-
finities and at elevated insulin levels, insulin can also bind and activate
IGF-1 receptors [51]. These observations are also relevant to insulin as
they suggest that hyperinsulinemia, which can be very pronounced in
ICU patients, may also involve IGF-1 signaling. Hence, insulin can exert
an immuno-regulating effect even in immune cells with a low abundance
of insulin receptors [52]. In relation to what has been said above, it is
clear that hyperinsulinemia could favor the inflammatory process
through the stimulation of the mTOR pathway, inducing a worsening of
the outcome of these patients. After all, at the base of COVID-19, there
is a virus-induced dysregulated inflammatory process, in which hyper-
insulinemia could act in an unfavorable way, promoting the dysregu-
lated inflammatory process.

At the same time, the question arises of the role of insulin resistance,
which is often found in long-standing diabetic patients and which
theoretically should induce an altered and reduced signal related to
insulin stimulation. However, there are conflicting data in this regard
and the need to prove everything [53].

Furthermore, the role of hyperglycemia in this category of patients
should be clarified. In that, hyperglycemia could induce an up-
regulation of mTOR receptors and therefore, favor the inflammatory
stimulus by insulin [47,54]. This hypothesis would be based on the fact
that the mTOR pathway plays a fundamental role in cellular metabolism
and hyperglycemia could represent a stimulus for the greater use of
this pathway [47]. At the same time, the up-regulation of mTOR re-
ceptors could not only constitute a greater inflammatory stimulus by
insulin, but at the same time could represent a pathway favoring viral
replication [5]. In fact, the mTOR pathway represents a fundamental
pathway in the processes of protein synthesis and transcription [5,47].

Therefore, as reported above, it can be deduced that the etiopatho-
genetetic mechanisms underlying diabetes could represent a favorable
substrate for a greater development of the inflammatory process already
dysregulated in COVID-19 with a more severe evolution of the disease.
However, numerous other studies are needed to demonstrate such
correlations.

4. Metformin and COVID-19

Among the oral antidiabetic drugs, the most prescribed in the world
is metformin, which is characterized by a high efficacy, low cost, good
tolerability profile. In general, metformin acts by reducing the levels
of postprandial insulin and peripheral insulin resistance, thus leading to
a reduction in blood sugar without causing clinically significant hypo-
glycemia; therefore, it acts as an anti-hyperglycemic agent and periph-
eral insulin sensitizer. Although it was introduced in the 1950s, its
mechanism of action is still not completely clear today and it also seems
to involve the inhibition of the mitochondrial respiratory chain, as
demonstrated in various organs and tissues including hepatocytes,
skeletal muscle, endothelial cells, bilo-pancreatic and neuronal cells
[55,56,57]. Its mechanism of action seems to be partly realized through
the inhibition of key genes of cellular metabolism, among which, the
most studied are those of the PI3K/Akt/mTOR pathway which through
the activation of TSC2 (Tuberous Sclerosis Complex 2, tuberin) nega-
tively regulate the activity of mTOR [58,59]. (Fig. 2) A possible anti-
inflammatory action of metformin is already known in the literature,
in fact, Isoda et al. demonstrated that metformin reduced IL-1β excretion
and inhibited nuclear translocation of nuclear factor κB (NF-κB),
inducing anti-inflammatory activity through inhibition of the mTOR
pathway [60].

Several studies have evaluated the impact of metformin in patients
with COVID-19 suffering from diabetes. Among the categories of pa-
tients considered, this drug has been re-evaluated for its immunomodu-
lationary action [61–69]. A retrospective study of 6,256 patients with type
2 diabetes and COVID-19 showed a 24% RR reduction in mortality (HR
0.76, 95% CI 0.60–0.96, p = 0.02) in patients using metformin versus
those not using it. The CORONADO study found that patients who were
being treated with metformin reported lower mortality [22]. Another
study, on the other hand, did not observe differences in mortality bet-
ween those who used Metformin and those who did not [67]. Some
meta-analyzes performed in this regard also found a significant reduc-
tion in the risk of death among metformin users compared to non-users
[70–72].

5. Other antidiabetic medications and COVID-19

Besides metformin, other anti-diabetic drugs also act on the mTOR
signaling pathway.

In particular, Pioglitazone is known to protect against hypoxemia/
reoxygenvation lesions by potentiating autophagy through the AMPK-mTOR signaling pathway [73]. The study of Xiaojing Xi et al. has shown that pioglitazone, a PPAR-γ agonist used in the treatment of type 2 diabetes, could protect against ischemic renal disease by inhibiting renal cell apoptosis and enhancing antioxidant effect. Furthermore, the same study demonstrated that pioglitazone significantly protected against H/R injury by enhancing autophagy in a normal rat kidney proximal tubular cells NRK-52E model of H/R. The mechanisms underlying the cytoprotective effect of pioglitazone was due to Pioglitazone’s promotion of cell autophagy through the AMPK/mTOR pathway. Activation of AMPK could inhibit mTOR and stimulate autophagy. Thus autophagy may participate in pioglitazone-induced cytoprotection against H/R damage in NRK-52E cells. Regulation of autophagy could represent a new strategy in the treatment of ischemic kidney disease [73]. Therefore, also Pioglitazone, could through its mechanism of action indicated above represent a further weapon in the context of COVID-19. Although there are currently no data regarding the use of Pioglitazone in patients with COVID-19.

Also dipeptidyl peptidase-4 inhibitors, through the mTOR pathway, appear to restore insulin secretion by improving autophagy in mice induced by a high-fat diet [74]. In fact, the study of Limei Liu et al. showed that phosphorylation of the mTOR pathway stimulated insulin secretion in obese mice [74]. Therefore, even this drug, due to its mechanism of action, could represent a resource in the context of COVID-19. However, there is currently a lack of data regarding the use of DPP-4 in patients with COVID-19.

Others anti-diabetic drugs, such as peroxisome proliferator-activated receptor γ (PPARγ) activator and glucagon-like peptide 1 receptor (GLP-1R) agonist, have been shown to upregulate ACE2 in animal models, which may increase the risk of SARS-CoV-2 infection [75].

Although it is well known that in addition to metformin, other antidiabetic drugs also act on the mTOR pathway, however little is known about their potential role in COVID-19 than metformin.

6. Conclusion

There is still a lot to learn about the etiopathogenic mechanisms underlying COVID-19 in patients with diabetes. What emerges from this review is that the etiopathogenic mechanisms that characterize diabetics in this category of patients, seem to favor the dysregulated inflammatory process underlying COVID-19 and, moreover, this would also partly explain the worst outcome observed in such patient category. The mTOR pathway would seem to play a key role. From the data available, it appears that the activation and stimulation of this pathway instigates/activates an inflammatory process that is already dysregulated, while its inhibition could regulate this dysregulated inflammatory process. However, much remains to be clarified about the mechanisms of the mTOR pathway and its role in COVID-19. The action of metformin and other antidiabetic drugs such as pioglitazone, DPP-4 inhibitors, GLP-1 agonists and SGLT2 inhibitors, could have an important impact on the evolution of COVID-19 through their action on the mTOR pathway. However, while for metformin there are a series of data regarding its use in patients with COVID-19, on the other hand, for the other antidiabetic drugs, data regarding their use in patients with COVID-19 are almost absent. This review has the purpose of being able to represent a starting point and a stimulus to deepen this topic, in order to understand the etiopathogenesis underlying COVID-19 in diabetic patients and in order to be able to find new weapons to deal with this disease.

Funding

The authors received no funding from an external source.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Federico II COVID Team (Ametrano Luigi, Amicone Maria, Borrelli Francesco, Buonono Antonio Riccardo, Cattaneo Letizia, Conte Maria Carmela Domenica, Cotugno Mariarosaria, Di Filippo Giovanni, Di Filippo Isabella, Esposito Nunzia, Festa Lidia, Fusco Ludovica, Foglia Maria, Gallicchio Antonella, Gentile Ivan, Giaccone Agnese, Iuliano Antonio, Lanzardo Amedeo, Liciardi Federica, Mercinelli Simona, Minervini Fulvio, Nobile Mariano, Piccione Amerigo, Pinchera Biagio, Reynaud Laura, Saleni Fabrizio, Sardanelli Aleszia, Sasso Marino, Schiano Moriero Nicola, Scordino Fabrizio, Scotto Riccardo, Stagnaro Francesca, Tosone Grazia, Vecchiotti Ilaria, Viceconte Giulio, Zappulo Emanuela, Zotta Irene).

References

[1] Mashayekhi-Sardoo Habibehe, Hosseinjani Hasemoddin. A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19. J Basic Clin Physiol Pharmacol 2021. https://doi.org/10.1515/jbcpp-2021-0495.
[2] Le Sage V, Cinis A, Amorim R, Mouland A. Adapting the stress response: viral subversion of the mTOR signaling pathway. Viruses 2016;8(6):152. https://doi.org/10.3390/v8060152.
[3] Karam BS, Morris RS, Bramante CT, Paskarich M, Zolfaghari EJ, Lotfi-Enmar S, et al. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses. J Med Virol 2021;93(4):1843–6.
[4] Terrazzano G, Rubino V, Palacian AT, Giovazzino A, Carriero F, Ruggiero G. An open question: is it rational to inhibit the mTOR-dependent pathway as COVID-19 therapy? Front Pharmacol 2020;11:856.
[5] Maiese K. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment. Curr Neuropsych Res 2020;17(3):332–7.
[6] Horvath S, Lu AT, Cohen H, Raj K. Rapamycin Retards Replicative Senescence, Proliferation and Differentiation. Aging 2019;11(10):3238–49.
[7] Schinaman JM, Rana A, Ja WW, Clark RL, Walker DW. Rapamycin Modules Tissue Aging and Lifespan Independently of the Gut Microbiota in Drosophila. Sci Rep 2019;9:7824.
[8] Karsulovic C, Lopez M, Tempio F, Guerrero J, Goecke A. mTORC1 Inhibitor Sirolimus Deprogramms Monocytes in “Cytokine Storm” in SARS-CoV2 Secondary Hemophagocytic Lymphohistiocytosis-like Syndrome. Clin Immunol 2020;218:108599.
[9] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet 2020;395(10223):497–507. https://doi.org/10.1016/S0140-6736(20)30185-5.
[10] Lin C-Y, Hsu S-C, Lee H-S, Lin S-H, Tsai C-S, Huang S-M, et al. Enhanced Expression of Glucose Transporter-1 in Vascular Smooth Muscle Cells via the Akt/Tuberosis Complex Subunit 2 (TSC2)/Mammalian Target of Rapamycin (mTOR)/Ribosomal S6 Protein Kinase (S6K) Pathway in Experimental Renal Failure. J Vasc Surg 2013;57:475–85.
[11] Liu Y, Yang F, Zou S, Qi L. Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-Atherosclerotic Effects and Its Clinical Application. Front Pharmacol 2018;9:1520.
[12] Zheng Y, Li R, Liu S. Immune regulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines. J Med Virol 2020;92(4):495–500.
[13] Rovio-Veres V, Rovio GN. Lower COVID-19 Mortality in Italian Forested Areas Suggests Immunoprotection by Mediterranean Plants. Environ Chem Lett 2021;19:699–710. https://doi.org/10.1007/s10311-021-01063-0.
[14] Zhou Y, Hu Y, Shen J, Huang Y, Martin W, Cheng F. Network-Based Drug Repurposing for Novel Coronavirus 2019-NCOV/SARS-CoV-2. Cell Discov 2020;6:85.
[15] Ramaiah MJ. MTOR Inhibition and P53 Activation, MicroRNAs: The Possible Recommendation. J Med Internet Res 2020;22(8):e21169. https://doi.org/10.1016/j.genrep.2020.100765.
[16] Yarmohammadi A, Yarmohammadi M, Fakhri S, Khan H. Targeting Pivotal Inflammatory Pathways in COVID-19: A Mechanistic Review. Eur J Pharmacol 2020;845:173626. https://doi.org/10.1016/j.ejphar.2020.173626.
[17] Gates LE, Eamed AA. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the COVIDx Network Algorithm for Drug Repurposing Recommendation. J Med Internet Res 2020;22(8):e21169. https://doi.org/10.2196/21169.
[18] Ramaiah MJ. MTOR Inhibition and P53 Activation, MicroRNAs: The Possible Therapy against Pandemic COVID-19. Gene Rep 2020;20:100765. https://doi.org/10.1016/j.genrep.2020.100765.
Diabetes Research and Clinical Practice 186 (2022) 109813

5

[38x152][42] Holman N, Knighton P, Kar P, O Zhu L, She AG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19. Hum Cell 2021;34(2):698–703.

[38x176][41] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors and in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes Metab Syndr 2020;14(6):2172–83.

[38x200][40] Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of patients with COVID-19. Diabetes Care 2020;43(11):1641–4.

[38x224][39] Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19? A systematic review and meta-analysis. Diabetes Obes Metab 2020;22:1915–24.

[38x312][35] Singh AK, Singh R. Is metformin ahead in the race as a repurposed host-directed therapy for COVID-19? medRxiv 2020.

[38x407][31] Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in patients hospitalized with COVID-19 in a diverse population with COVID-19 and diabetes. medRxiv 2020 https://doi.org/10.1101/2020.07.29.20164020.

[38x439][30] Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28 2020. Morb Mortal Wkly Rep 2020;69(13):382–3.

[38x463][28] Mancusi C, Grassi G, Borghi C, Ferri C, Muiesan ML, Volpe M, et al. SARS-RAS coronavirus RNA is detected in plasma of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14(3):108268.

[38x495][27] Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract 2020;167:108382. https://doi.org/10.1016/j.diabres.2020.108382.

[38x519][26] Tsai S, Keefe J, Curley M, Weaver A, et al. Risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care 2020;43(7):1382–91.

[38x559][25] Philipose Z, Smati N, Wong CSJ, et al. Obesity, old age, and frailty are the true risk factors for COVID-19 mortality and not chronic disease or ethnicity. medRxiv 2020 https://doi.org/10.1101/2020.08.12.20156257.

[38x583][24] Cho SH, Raybuck AL, Blagih J, Kembi E, Haase VH, Jones RG, et al. Hypoxia-inducible factors in CD4+ T cells promote metabolism, switch cytokine secretion, and T cell help in humoral immunity. Proc Natl Acad Sci USA 2011;108(19):7755–60.

[38x606][23] Taul S, Clemente-Casares X, Zhou AC, LeI H, Ahn JJ, Chan YT, et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab 2018;28(6):934–45.

[38x622][22] Keitumets VM, Stone EL, Birnser DM, McGarrill MA, Chen IL, Stockmann C, et al. Foxo transcription factors control regulatory T cell development and function. Immunity 2010;33(6):890–904.

[38x646][21] Mohammad S, Azir R, Al Shommari A, Malik SS, Haji E, Khan AI, et al. Obesity and COVID-19: what makes obese host so vulnerable? Immun Ageing 2021;18(1). https://doi.org/10.1186/s40164-020-00212-x.

[38x686][20] Pinede-Hermida S, López IP, Alfaro-Armedo E, Torres R, Iniguez M, Alvarez-Erviti L, et al. IGFIIR deficiency attenuates acute inflammatory response in ableomycin-induced lung injury mouse model. Sci Rep 2017;7(1):1. https://doi.org/10.1038/s41598-017-04651-4.

[38x726][19] Tsai S, Clemente-Casares X, Zhou AC, Lei H, Ahn JJ, Chan YT, et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab 2018;28(6):934–45.

[38x752][18] Keitumets VM, Stone EL, Birnser DM, McGarrill MA, Chen IL, Stockmann C, et al. Foxo transcription factors control regulatory T cell development and function. Immunity 2010;33(6):890–904.

[38x778][17] Liu J, Zhu B, Gao S, et al. PI3K–α/mTOR/BRD4 inhibitor. bioRxiv. 2021;2021.03.02.433604.

[38x802][16] Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19 mortality and not chronic disease or ethnicity. medRxiv 2020 https://doi.org/10.1101/2020.07.29.20164020.

[38x826][15] Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of patients with COVID-19. J Clin Endocrinol Metab 2020;95(11):4033–43.

[38x850][14] Chen YM, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv 2020.

[38x874][13] Roncon L, Zuin M, Rigattelli G, Zanlini G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020;127:104554. https://doi.org/10.1016/j.jcv.2020.104554.

[38x908][12] Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging 2020;12(7):6049–57.

[38x932][11] Kumar A, Arora A, Sharma O, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr 2020;14(4):535–45.

[38x956][10] Huang L, Lim MA, Pranata R, et al. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2020;14(4):395–403.

[38x980][9] Roncon L, Zuin M, Rigattelli G, Zanlini G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020;127:104554. https://doi.org/10.1016/j.jcv.2020.104554.

[38x1014][8] Bode B, Garrebert V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14(4):831–21.

[38x1048][7] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.

[38x1082][6] Zhu L, She AG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;32(4). 537.e9.

[38x1116][5] Holman N, Knighton P, Kar P, O Zhu L, She AG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;32(4). 537.e9.

[38x1150][4] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.

[38x1184][3] Bode B, Garrebert V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14(4):831–21.

[38x1218][2] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.

[38x1252][1] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.

[38x1286][0] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.

[38x1320][0] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.
[73] Xi X, Zou C, Ye Z, Huang Y, Chen T, Honglin Hu. Pioglitazone protects tubular cells against hypoxia/reoxygenation injury through enhancing autophagy via AMPK-mTOR signaling pathway. Eur J Pharmacol 2019;863:172695.

[74] Liu L, Liu J, Xiaoxing Yu. Dipeptidyl peptidase-4 inhibitor MK-626 restores insulin secretion through enhancing autophagy in high fat diet-induced mice. Biochem Biophys Res Commun 2016;470(3):516–20.

[75] Shao S, Yang Q, Pan R, Xuefeng Yu, Chen Y. Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes. Front Endocrinol (Lausanne) 2021;6(12):731974.